Renaissance Venture Capital

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Autobooks, Inc. is a provider of integrated payment and accounting software tailored for small businesses. Founded in 2015 and based in Detroit, Michigan, the company offers an intelligent, cloud-based platform that seamlessly integrates with bank accounts, facilitating cash flow management, account reconciliation, and business growth. Through its services, Autobooks enables financial institutions to deliver essential back-office functions and an e-commerce platform directly within their digital banking channels. Its product suite includes features for invoicing, bill pay, merchant services, treasury products, and automated accounting, all designed to simplify financial management for small businesses. The company, originally known as Automated Booking, Inc., rebranded to Autobooks, Inc. in March 2018.

Strata Oncology, Inc. is a precision oncology company focused on enhancing cancer care by facilitating access to precision medicine clinical trials and expediting drug approval processes. Based in Ann Arbor, Michigan, the company develops a comprehensive precision oncology platform that supports routine testing and efficient use of molecular data. Strata's offerings include The Strata Trial, a genomic testing program for systematic precision oncology implementation, and StrataNGS, a targeted assay for sequencing DNA and RNA from biopsies. Additionally, StrataPOINT integrates electronic medical record histories with molecular profiling to ensure eligible patients are tested and considered for trial enrollment. The company features a portfolio of pharma-sponsored therapeutic protocols, known as Strata Partnered Trials, aligned to specific biomarkers. Strata also operates The Strata Lab, a cancer sequencing facility, and maintains the Strata Precision Oncology Network, a collaborative entity aimed at promoting precision medicine initiatives. Formerly known as Strata Oncology Research, Inc., the company rebranded in 2016 and has been incorporated since 2015.

Next Coast Ventures, established in 2015 and headquartered in Austin, Texas, is a venture capital firm focusing on early-stage technology companies. It invests in 'Next Coast' markets, targeting high-growth startups in Texas and other non-coastal regions. The firm's investment strategy is guided by macro trends and themes, with a preference for sectors such as information technology, workplace, healthcare, retail, and marketplace software. Next Coast Ventures provides not only capital but also hands-on support and industry connections to its portfolio companies, aiming to facilitate their growth and success.

Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company dedicated to developing and commercializing therapies for liver and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company is focused on its lead product candidate, MSDC-0602K, an oral small molecule currently undergoing Phase 2b clinical trials for the treatment of nonalcoholic steatohepatitis (NASH) with fibrosis. MSDC-0602K operates as a next-generation insulin sensitizer, aiming to address the underlying pathophysiology of NASH, which is characterized by fat accumulation and inflammation in the liver and can progress to severe conditions such as cirrhosis or liver cancer. Cirius Therapeutics seeks to provide innovative solutions for healthcare providers managing liver and metabolic diseases.

Millendo Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for endocrine diseases resulting from hormone dysregulation. The company focuses on creating distinct and transformative therapies that address significant unmet medical needs in this area. By leveraging scientific advancements, Millendo aims to develop novel compounds that can effectively treat complex conditions, ultimately enhancing clinical care and improving the quality of life for patients, families, and caregivers.

Atlas Venture, established in 1980, is a Cambridge, Massachusetts-based venture capital firm with a global presence. It manages over $2 billion in committed capital across multiple funds. The firm specializes in early-stage investing, focusing on life sciences and technology sectors. Atlas Venture creates and invests in biotech startups led by promising entrepreneurs, aiming to build scalable businesses and realize value. It typically invests $500,000 to $5 million in seed and early-stage rounds, with follow-on financing potentially reaching $10 to $20 million per company. Since 1995, Atlas Venture has been involved with over 350 companies, with 50 acquisitions and 40 IPOs.

ArborMetrix, Inc. is a data analytics company that focuses on enhancing outcomes and measuring value within the healthcare sector. Founded in 2011 and based in Ann Arbor, Michigan, the company offers a suite of technology solutions that include data collection and integration, rigorous performance measurement, and analytics. ArborMetrix's platform provides essential tools such as EpisodeMetrix for cost analysis of healthcare episodes, RegistryMetrix for developing specialized clinical registries, and SurgicalMetrix for analyzing surgical performance. Their services aim to provide actionable insights that enable hospitals, health plans, physician organizations, and specialty societies to optimize financial performance, improve clinical outcomes, and support value-based reimbursement. Additionally, ArborMetrix offers solutions for clinical quality improvement, patient engagement, and post-market surveillance, serving a diverse range of clients within the U.S. healthcare landscape.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, that specializes in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics, translational, and clinical research. The company focuses on creating innovative molecular biology reagents, protocols, and diagnostic tools to enhance the efficiency and accuracy of genomic analysis. Its product offerings include various RNA and DNA library preparation kits, amplicon panels, hybridization capture kits, and specialized tools for cancer gene profiling and metagenomics. Swift Biosciences' technologies aim to streamline sample preparation processes and improve data quality from NGS instruments, supporting a wide range of applications such as circulating tumor cells and whole-genome sequencing. The company distributes its products through a network of distributors across Asia Pacific, Europe, the Middle East, and South America. Established in 2009, Swift Biosciences is committed to advancing molecular research and diagnostics.

Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.

RPM Ventures, established in 2000 and headquartered in Ann Arbor, Michigan, is an early-stage venture capital firm with a $750 million fund under management. The firm specializes in disrupting multi-billion-dollar markets within sectors such as FinTech, InsurTech, Real Estate Tech, and Mobility & Transportation. RPM Ventures primarily invests in seed and early-stage companies, with a focus on software and technology businesses. The firm targets companies that have the Midwest's Fortune 500 manufacturing base as their primary customer or are based on technology developed at the Midwest's premier research centers. RPM Ventures is recognized as an industry thought leader, with a history of investing in innovative companies that drive market disruption.

Arboretum Ventures, established in 2002, is a Michigan-based venture capital firm with a focus on the healthcare sector. It invests in seed, early, and growth-stage companies across the United States, with a particular emphasis on the Midwest and Michigan. The firm targets healthcare services, medical devices, diagnostics, healthcare IT, therapeutics, technology-based healthcare services, and life science tools. Arboretum Ventures typically invests between $5 million and $15 million in equity per company.